The sensitivities of apoA2-ATQ/AT and CA19-9 for stage I pancreatic cancer were 47.4% and 36.8%, respectively, 50% and 46.7% for stage I/II, respectively, and 46.7% and 33.3% for TS1, respectively. This evidence concerns the gene APOA2 and familial pancreatic carcinoma.